Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · IEX Real-Time Price · USD
0.600
+0.011 (1.94%)
At close: May 24, 2024, 3:59 PM
0.598
-0.002 (-0.35%)
After-hours: May 24, 2024, 6:12 PM EDT

Company Description

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro, Inc.
Alzamend Neuro logo
Country United States
Founded 2016
IPO Date Jun 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Stephan Jackman

Contact Details

Address:
3500 Lenox Rd. Ne, Suite 1500
Atlanta, Georgia 30326
United States
Phone 844-722-6333
Website alzamend.com

Stock Details

Ticker Symbol ALZN
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
IPO Price $5.00
CIK Code 0001677077
CUSIP Number 02262M308
ISIN Number US02262M4078
Employer ID 81-1822909
SIC Code 2834

Key Executives

Name Position
Stephan Jackman Chief Executive Officer and Director
David J. Katzoff Chief Financial Officer
Milton Charles Ault III Founder and Vice Chairman
Henry C. W. Nisser Esq. Executive Vice President, General Counsel and Director
Kenneth S. Cragun CPA Senior Vice President of Finance

Latest SEC Filings

Date Type Title
May 22, 2024 8-K Current Report
May 15, 2024 8-K Current Report
May 13, 2024 8-K Current Report
May 10, 2024 PRE 14A Other preliminary proxy statements
May 10, 2024 8-K/A [Amend] Current report
May 10, 2024 424B5 Filing
May 9, 2024 8-K Current Report
May 9, 2024 8-K Current Report
May 7, 2024 424B5 Filing
May 7, 2024 8-K Current Report